After Great Dane success, cancer doc eyes brain tumors

June 27, 2013
After Great Dane success, cancer doc eyes brain tumors
After compassionately and successfully treating his Great Dane, Star, Michael Graner is moving the cancer immunotherapy technique into a clinical trial for human glioblastoma Credit: Michael Graner, Ph.D.

(Medical Xpress)—Two University of Colorado Cancer Center publications set stage for K9 cancer vaccine test with human glioblastoma. Michael Graner, PhD, is a CU Cancer Center investigator and associate professor of neurosurgery at the CU School of Medicine. So when his 12-year-old Great Dane got sick, he knew what to do.

"We got Star from the Mid-Atlantic Great Dane Rescue," Graner says. "She got her name because she was always smiling, like a movie star waiting for photos. She'd already been to so many shelters, we didn't want to change her name again and so we kept it."

At 12, after many years with the Graners, Star had already reached about double the for the breed. When she collapsed during a coughing fit, Graner discovered the cause: , specifically advanced bronchoalveolar with metastasis to the lymph nodes. The prognosis was grim, with a median survival from diagnosis of only about 6-27 days. And Star was well past the age when she could've tolerated chemotherapy or radiation.

"With that diagnosis, chemotherapy has only a 10-15 percent response rate and she was old – with her prognosis and the drug side effects let's just say chemotherapy wasn't viable. We didn't want to make her any sicker," Graner says.

So he turned to his specialty, immunotherapy. The idea is to circumvent the immune system's nasty habit of recognizing cancer as its own tissue instead of seeing it as an invading disease and attacking it. By using engineered vaccines to prime the immune system to recognize tumors, cancer immunologists are using the body's own defenses to clear itself of the disease. In this case, the treatment was fairly simple and carried almost no chance of side effects that could make Star any less comfortable: a 10-gram sample of her tumor was enriched into an injectable vaccine that contained a high concentration of in "chaperone-rich cell lysate" (CRCL), which tell the immune system's T-cells what to attack.

"We expected to see solid metastases within days," said Graner. "But, you know, then the months started to go by. The important thing to us was her quality of life was really good. It was really simple and it certainly didn't hurt." You can read about the treatment and results in a paper in the International Journal of Hyperthermia, on which Graner collaborated with Laura Epple, DVM, now a PhD candidate in the Graner Lab.

Finally, at 44 weeks – more than ten times the best they should have hoped for! – Star showed aggressive progression of the disease. At nearly a year after the diagnosis of a disease that should have killed her within a month, Graner and his family made the difficult decision to euthanize Star.

"We still have a couple of her cell lines here in the lab," Graner says. "In that way, she's kind of immortal."

Another chance for Star's immortality comes from her potential for her experience to extend the lives of human brain cancer patients. See, Graner has continued his studies with the CRCL-rich vaccines of the type that led to Star's dramatic and prolonged improvement.

"It's one thing to treat mice in these fake systems and another to treat a naturally arising tumor that had a poor prognosis," Graner says. Along with Kevin Lellehei, chair of Neurosurgery at the University of Colorado School of Medicine, Graner recently submitted a proposal to the FDA to treat human glioblastoma with CRCL vaccine. "Star's success may make it much easier for the FDA to approve similar treatment with human glioblastoma," Graner says.

In Graner's proposed trial, human brain cancer patients would continue to receive the standard of care to treat the disease and would also intersperse treatment with the experimental vaccine, whose benefit he hopes to show, but which is also unlikely to cause additional harm.

He describes a similar protocol that failed to get approval from the European Medicines Agency.

"This isn't a brand new idea," Graner says. "But until now there had been some gaps in our understanding." One of these gaps was the fact that while previous researchers had hypothesized that tumor chaperone proteins carried the peptides that, when enriched and reinjected as a vaccine, could sensitize the immune system to tumor tissues, previous studies hadn't identified these peptides.

In another recent paper, also published in the International Journal of Hyperthermia, Graner describes what he calls, "taking these proteins and beating the peptides off them to see what they are." Sure enough, many of the peptides isolated from tumor samples were derived from proteins unique to cancer – this means that a CRCL vaccine was likely to result in an immune response directed specifically at tumor tissue and not at surrounding, healthy tissues.

Graner writes that, "Parental proteins [that would be targets for the immune cells] are components of major signaling networks of vital importance for cancer cell survival, proliferation, and migration."

With the immune system sensitized, the unique genetic mutations that allow cells to act cancerous would also mark them for destruction. With this research gap filled and with Star demonstrating the vaccine's effect, Graner is hopeful his proposed trial will make it to human patients soon.

"She was a real sweetie," Graner says of Star. "Hopefully her contribution to the world has just begun."

Explore further: Brain cancer breakthrough: Experimental vaccine trains immune system to target remaining tumor cells after surgery

Related Stories

Brain cancer breakthrough: Experimental vaccine trains immune system to target remaining tumor cells after surgery

November 14, 2012
UC Irvine oncologists are looking for new ways to treat glioblastoma multiforme, the deadliest type of brain cancer. While surgery followed by chemotherapy and radiation is the current standard of care, it doesn't fully eliminate ...

Immune system to fight brain tumors

May 30, 2013
Research at Lund University in Sweden gives hope that one of the most serious types of brain tumour, glioblastoma multiforme, could be fought by the patients' own immune system. The tumours are difficult to remove with surgery ...

UC Irvine opens clinical trial of novel treatment for brain cancer

October 10, 2012
UC Irvine doctors are enrolling patients with the deadly brain tumor glioblastoma multiforme in a clinical trial of a vaccine that may prevent the cancer's return or spread after surgery.

Researchers study vaccine as potential weapon against aggressive brain tumors

July 24, 2012
Researchers at Northwestern Brain Tumor Institute (NBTI) are seeking to understand if a vaccine made from a patient's own blood cells may slow the growth of a type of brain tumor. The trial is studying the vaccine's effect ...

Poliovirus vaccine trial shows early promise for recurrent glioblastoma

May 21, 2013
An attack on glioblastoma brain tumor cells that uses a modified poliovirus is showing encouraging results in an early study to establish the proper dose level, researchers at Duke Cancer Institute report.

Recommended for you

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.